News

Steris (STE) reported $1.42 billion in revenue for the quarter ended March 2024, representing a year-over-year increase of 2.5%. EPS of $2.41 for the same period compares to $2.30 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $1.46 billion, representing a surprise of -3.07%. The company has not delivered EPS surprise, with the consensus EPS estimate being $2.41.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Steris performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Healthcare: $1.01 billion versus $947.46 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +13.9% change.
• Revenues- Life Sciences: $160.63 million compared to the $161.56 million average estimate based on three analysts. The reported number represents a change of +2% year over year.
• Revenues- Dental: $103.79 million versus $107.16 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +0.2% change.
• Revenues- Applied Sterilization Technologies: $250.90 million versus $248.19 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +4.9% change.
• Revenues- Life Sciences- Service: $45.97 million versus $44.74 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +13.2% change.
• Revenues- Life Sciences- Capital equipment: $44.26 million versus $50.35 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -8.4% change.
• Revenues- Life Sciences- Consumables: $70.40 million versus $67.53 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +2.7% change.
• Revenues- Healthcare Products- Capital equipment: $331.70 million versus $284.16 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +19.4% change.
• Revenues- Healthcare Products- Consumables: $332.68 million versus the two-analyst average estimate of $321.13 million. The reported number represents a year-over-year change of +13.8%.
• Revenues- Healthcare Products- Service: $343.48 million versus $343.53 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +9.2% change.
• Operating income / (loss)- Healthcare: $245.22 million versus the two-analyst average estimate of $219.64 million.
• Operating income / (loss)- Life Sciences: $64.49 million versus the two-analyst average estimate of $62.38 million.

View all Key Company Metrics for Steris here>>>

Shares of Steris have returned -0.9% over the past month versus the Zacks S&P 500 composite's -0.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Top 5 Dividend Stocks for Your Retirement

Zacks targets 5 well-established companies with solid fundamentals and a history of raising dividends. More importantly, they have the resources and will to likely pay them in the future.

Click now for a Special Report packed with unconventional wisdom and insights you simply won’t get from your neighborhood financial planner.

See our Top 5 now – the report is FREE >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.